T-47D Orthotopic Mouse Model Service for Breast Cancer

The T-47D orthotopic mouse model offers a meticulously characterized, hormone-dependent preclinical platform for dissecting luminal A breast cancer biology, enabling robust assessment of endocrine therapies, selective estrogen receptor degraders, and combination regimens within an authentically reconstructed mammary microenvironment. Alfa Cytology constructs and manages this orthotopic xenograft system with standardized estrogen supplementation protocols, authenticated cell line stocks, and comprehensive molecular endpoint analysis, delivering translationally relevant datasets that bridge the gap between in vitro characterization and in vivo therapeutic profiling for hormone-receptor-positive malignancies.

Overview of T-47D Orthotopic Mouse Model for Breast Cancer

The T-47D cell line was originally established in 1978 from the pleural effusion of a 54-year-old Caucasian female diagnosed with infiltrating ductal carcinoma of the breast. Molecularly classified within the luminal A intrinsic subtype, T-47D is characterized by robust expression of both estrogen receptor alpha (ER^α) and progesterone receptor (PR), with absence of HER2/neu amplification. Genetically, the line harbors a loss-of-function TP53 missense mutation (L194F) that impairs DNA damage response and apoptotic signaling, alongside an activating PIK3CA hotspot mutation (H1047R) that drives constitutive PI3K/AKT/mTOR pathway activation. Additional alterations in RB1 and CDKN2A further perturb cell cycle checkpoint control. The hypotriploid karyotype and epithelial-like morphology underpin its stable luminal differentiation phenotype, making T-47D a canonical reference standard for investigating hormone receptor-driven transcriptional programs, progesterone-specific signaling responses, and acquired endocrine resistance mechanisms.

Fig 1. MORAb-202 suppressed orthotopic xenograft tumor growth of T47D cells. (Matsunaga, Yuki, et al., 2021)

Orthotopic engraftment of T-47D cells into the murine mammary fat pad reconstitutes the steroid hormone milieu, stromal architecture, and vascular network characteristic of clinical luminal A tumors. A defining feature of this model is its strict dependence on exogenous estrogen supplementation—typically delivered via slow-release 17β-estradiol pellets—to sustain tumor viability and proliferation in vivo. Tumors generally establish within 14–21 days post-implantation and progress to endpoint volumes (approximately 1,000–1,500 mm³) over a 6–8 week observation period. The model faithfully recapitulates the low proliferative index, well-differentiated histology, and hormone-responsive growth kinetics of patient-derived luminal malignancies, rendering it indispensable for preclinical evaluation of aromatase inhibitors, selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and CDK4/6 inhibitor combinations.

Cell Line Information: T-47D

T-47D stands as one of the most extensively utilized luminal A breast cancer cell lines in oncology research, distinguished by its exceptionally high and stable progesterone receptor expression and pronounced hormonal responsiveness. The table below consolidates its essential biological, genetic, and culture parameters:

Our Services

Alfa Cytology offers a fully integrated T-47D orthotopic model service encompassing cell line authentication, estrogen pellet implantation, surgical mammary fat pad inoculation, longitudinal tumor monitoring, therapeutic dosing, and multi-layered endpoint analysis. Our scientists engineer each study around your compound's mechanism of action—whether you are profiling a next-generation SERD, an aromatase inhibitor, or a CDK4/6 combination strategy—delivering rigorous, publication-quality datasets that advance your preclinical pipeline with mechanistic clarity.

Workflow of T-47D Orthotopic Mouse Model Construction

Construction of the T-47D orthotopic model requires meticulous attention to hormonal preconditioning and sterile surgical technique to achieve consistent engraftment and physiologically relevant tumor growth. The protocol proceeds through the following sequential stages:

1. Cell Expansion and Quality Verification: T-47D cells are propagated in RPMI 1640 medium supplemented with 10% FBS and insulin, harvested during logarithmic growth, and authenticated via STR profiling. Mycoplasma negativity is confirmed by PCR, and ER^α/PR expression is validated by flow cytometry or Western blot prior to in vivo use. Cells are washed, counted, and resuspended in serum-free medium for injection.
2. Estrogen Pellet Implantation and Hormone Priming: Female athymic nude or NOD/SCID mice (5–7 weeks old) are anesthetized, and a slow-release 17β-estradiol pellet (typically 0.36 mg, 60-day release) is implanted subcutaneously in the interscapular region 48–72 hours prior to cell inoculation. This hormonal priming is essential to establish the estrogen-rich microenvironment required for T-47D engraftment and sustained proliferation.
3. Orthotopic Mammary Fat Pad Injection: Under general anesthesia, a small skin incision is made over the inguinal mammary fat pad. A suspension of 5 × 10⁶ T-47D cells (in 30–50 µL total volume, mixed 1:1 with Matrigel basement membrane matrix) is slowly injected into the fat pad using a 27-gauge needle. The skin is closed with surgical clips, and mice recover on a heated pad under continuous observation.
4. Tumor Monitoring and Cohort Randomization: Tumor establishment is monitored by palpation beginning on day 10–14 post-implantation. Once tumors reach 50–100 mm³, mice are randomized into treatment cohorts based on tumor volume to ensure statistically balanced baseline distributions across all experimental arms.
5. Therapeutic Intervention and Longitudinal Assessment: Test compounds are administered according to the predefined protocol (dose, route, frequency, and duration). Tumor dimensions are measured twice weekly with digital calipers, and body weights are recorded concurrently. Optional estrogen pellet replacement is performed at 60-day intervals to maintain sustained hormone levels throughout the study duration.
6. Necropsy and Tissue Procurement: Upon reaching study endpoints (tumor volume ~1,500 mm³, humane moribund criteria, or scheduled termination), mice are euthanized. Primary tumors are excised, weighed, and photographed. Regional lymph nodes, uterus (for estrogen bioavailability confirmation), lungs, liver, and other relevant organs are collected for metastasis and pharmacodynamic assessment.
7. Histopathological and Molecular Endpoint Analysis: Tumor tissues are fixed in formalin for H&E staining and immunohistochemistry (ER^α, PR, Ki-67, phospho-RB, cleaved caspase-3), or snap-frozen for Western blot, qPCR, and RNA-seq. Blood samples may be collected for pharmacokinetic profiling and circulating estradiol level verification.
8. Data Integration and Reporting: All tumor growth curves, body weight trajectories, histopathology scores, and molecular biomarker data are compiled into a comprehensive study report with statistical analysis. Tumor growth inhibition (TGI) and tumor growth delay (TGD) metrics are calculated alongside receptor occupancy and pathway activation indices to quantify therapeutic efficacy and mechanism of action.

Fig 2. T-47D Orthotopic Mouse Model construction workflow.

Case Study-T-47D Orthotopic Mouse Model Development

In a preclinical program focused on endocrine therapy innovation, the T-47D orthotopic model was employed to evaluate the antitumor activity of a novel oral selective estrogen receptor degrader (SERD) as a monotherapy and in combination with a CDK4/6 inhibitor. Following orthotopic engraftment under standardized estrogen supplementation and cohort randomization, treatment arms received escalating doses of the test SERD, the CDK4/6 inhibitor alone, the combination regimen, or vehicle control over an extended dosing period. Longitudinal tumor monitoring revealed dose-dependent growth suppression in the SERD monotherapy groups, with the combination cohort exhibiting substantially attenuated tumor volume expansion relative to both single-agent arms. Endpoint histopathological analysis demonstrated reduced Ki-67 proliferation indices, diminished phospho-RB staining, and increased apoptotic signaling in the combination-treated tumors, while ER^α receptor levels were markedly downregulated in the SERD-treated groups, confirming target engagement. These findings underscore the model's utility in dissecting endocrine sensitivity, combination synergy, and resistance biomarker profiles for hormone-receptor-positive breast cancer drug candidates.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your T-47D orthotopic breast cancer study provides access to a specialized CRO platform with deep expertise in hormone-dependent tumor model construction and endocrine therapy evaluation. Our distinguishing capabilities include:

• Authenticated T-47D cell banking with documented STR profiling, mycoplasma clearance, and passage-controlled expansion to preserve genetic stability and hormone receptor fidelity across cohorts.
• Standardized 17β-estradiol pellet implantation protocols with validated hormone level monitoring, ensuring consistent estrogen-dependent engraftment and reproducible tumor growth kinetics.
• Surgical expertise in mammary fat pad orthotopic implantation with demonstrated engraftment rates exceeding 85% under optimized hormonal conditions, minimizing animal usage while maintaining statistical power.
• Integrated steroid receptor profiling capabilities featuring validated IHC panels for ERα, PR, phospho-RB, Ki-67, and cleaved caspase-3, alongside molecular readouts for PI3K/AKT/mTOR pathway activation.
• Flexible combination study designs supporting sequential or concurrent administration of endocrine agents, CDK4/6 inhibitors, PI3K inhibitors, and emerging targeted therapies with customized dosing schedules.
• Dedicated project scientists providing weekly progress updates, interim data reviews, and collaborative interpretation of pharmacodynamic and efficacy endpoints to align preclinical outcomes with your clinical development strategy.

Contact Us

If your preclinical program requires a hormone-dependent luminal A breast cancer model that authentically recapitulates the in vivo endocrine microenvironment, we invite you to reach out to us to explore how Alfa Cytology can design and execute a tailored T-47D orthotopic study aligned with your therapeutic objectives. From protocol consultation and estrogen supplementation optimization through comprehensive endpoint analysis, our scientific team is committed to delivering actionable insights that de-risk your drug development decisions. Contact us today to initiate your project and leverage our specialized expertise in hormone-receptor-positive breast cancer preclinical research.

For research use only. Not intended for any clinical use.